These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32972198)

  • 1. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries.
    Carbonell-Estrany X; Rodgers-Gray BS; Paes B
    Expert Rev Anti Infect Ther; 2021 Apr; 19(4):419-441. PubMed ID: 32972198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
    Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Atwell JE; Lutz CS; Sparrow EG; Feikin DR
    Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.
    Mahmud S; Baral R; Sanderson C; Pecenka C; Jit M; Li Y; Clark A
    BMC Med; 2023 Apr; 21(1):138. PubMed ID: 37038127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
    Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Do LAH; Le NTN; Mahmud S; Mulholland K; Pecenka C; Clark A
    Vaccine; 2023 Nov; 41(46):6782-6790. PubMed ID: 37690873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory syncytial virus infection and the need for immunization in Korea.
    Kim HY; Yun KW; Cheong HJ; Choi EH; Lee HJ
    Expert Rev Vaccines; 2023; 22(1):327-340. PubMed ID: 36960592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
    Srikantiah P; Klugman KP
    BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus infections: characteristics and treatment.
    Chidgey SM; Broadley KJ
    J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational sciences approach to RSV vaccine development.
    Kurzweil V; Tang R; Galinski M; Wang K; Zuo F; Cherukuri A; Gasser RA; Malkin E; Sifakis F; Mendel DB; Esser MT
    Expert Rev Vaccines; 2013 Sep; 12(9):1047-60. PubMed ID: 24053398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
    Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
    BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.
    Giersing BK; Karron RA; Vekemans J; Kaslow DC; Moorthy VS
    Vaccine; 2019 Nov; 37(50):7355-7362. PubMed ID: 28302410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-to-date role of biologics in the management of respiratory syncytial virus.
    Boyoglu-Barnum S; Tripp RA
    Expert Opin Biol Ther; 2020 Sep; 20(9):1073-1082. PubMed ID: 32264720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
    Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
    Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Endpoints for Respiratory Syncytial Virus Prophylaxis Trials in Infants and Children in High-income and Middle-income Countries.
    Simões EA; Carbonell-Estrany X; Guilbert T; Mansbach JM; Piedra PA; Ramilo O; Welliver R
    Pediatr Infect Dis J; 2015 Oct; 34(10):1086-92. PubMed ID: 26121204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal RSV vaccine development. Where to from here?
    Gunatilaka A; Giles ML
    Hum Vaccin Immunother; 2021 Nov; 17(11):4542-4548. PubMed ID: 34499565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomes: a promising carrier for respiratory syncytial virus therapeutics.
    Joshi S; Bawage S; Tiwari P; Kirby D; Perrie Y; Dennis V; Singh SR
    Expert Opin Drug Deliv; 2019 Sep; 16(9):969-980. PubMed ID: 31382795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.